News

Qilu King-Phar successfully passes the US FDA inspection with no 483 observations

ABOUT US

News

Qilu King-Phar successfully passes the US FDA inspection with no 483 observations

Release time：

2017-04-19

March 23, Qilu Pharmaceutical announces that its subsidiary King-Phar Pharmaceutical successfully has passed the US FDA inspection with no 483 observations for the third time.

Many aspects including material management, production management, quality management, laboratory management and packaging system are involved in this inspection and the performance of cGMP is highly praised by the auditor.

‘One millionth of the manufacturer is 100% of the patients’. Qilu Pharmaceutical has always been attaching great importance to the product quality and the quality system is strictly constructed to be geared to international standards. With the aim of exploring the international high-end markets, Qilu Pharmaceutical will continue adhering to the normalization for high standard of the production and quality management in the future,

Qilu Pharmaceutical (Inner Mongolia) Passes U.S. FDA Inspection

Qilu Synva passed FDA inspection with Zero observation in June 2016

Related News

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”

2022-12-19

Qilu Pharmaceutical ranked 5th among China's top 100 list